Cargando…

Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era

Systemic juvenile idiopathic arthritis (sJIA) and its complication, macrophage activation syndrome (sJIA-MAS), are rare but sometimes very serious or even critical diseases of childhood that can occasionally be characterized by nonspecific clinical signs and symptoms at onset—such as non-remitting h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ailioaie, Laura Marinela, Ailioaie, Constantin, Litscher, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655921/ https://www.ncbi.nlm.nih.gov/pubmed/36361547 http://dx.doi.org/10.3390/ijms232112757

Ejemplares similares

Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis
por: Ailioaie, Laura Marinela, et al.
Publicado: (2022)

Intravenous Laser Blood Irradiation Increases Efficacy of Etanercept in Selected Subtypes of Juvenile Idiopathic Arthritis: An Innovative Clinical Research Approach
por: Chiran, Dragos Andrei, et al.
Publicado: (2013)

Infection, Dysbiosis and Inflammation Interplay in the COVID Era in Children
por: Ailioaie, Laura Marinela, et al.
Publicado: (2023)

Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis
por: Chiran, Dragos Andrei, et al.
Publicado: (2014)

Latest Innovations and Nanotechnologies with Curcumin as a Nature-Inspired Photosensitizer Applied in the Photodynamic Therapy of Cancer
por: Ailioaie, Laura Marinela, et al.
Publicado: (2021)

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
por: Ailioaie, Laura Marinela, et al.
Publicado: (2023)

Synergistic Nanomedicine: Photodynamic, Photothermal and Photoimmune Therapy in Hepatocellular Carcinoma: Fulfilling the Myth of Prometheus?
por: Ailioaie, Laura Marinela, et al.
Publicado: (2023)

Molecular and Cellular Mechanisms of Arthritis in Children and Adults: New Perspectives on Applied Photobiomodulation
por: Ailioaie, Laura Marinela, et al.
Publicado: (2020)

Celiac Disease and Targeting the Molecular Mechanisms of Autoimmunity in COVID Pandemic
por: Ailioaie, Laura Marinela, et al.
Publicado: (2022)

Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Ailioaie, Laura Marinela, et al.
Publicado: (2020)

Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges
por: Ailioaie, Laura Marinela, et al.
Publicado: (2021)

Photobiomodulation and Sports: Results of a Narrative Review
por: Ailioaie, Laura Marinela, et al.
Publicado: (2021)

The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Lazăr, Călin, et al.
Publicado: (2018)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome
por: Inoue, Natsumi, et al.
Publicado: (2023)

Juvenile Idiopathic Arthritis in the Era of International Cooperation
por: Uziel, Yosef
Publicado: (2017)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis
por: Jain, Deepak, et al.
Publicado: (2016)

Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis
por: Zeng, Hua-Song, et al.
Publicado: (2008)

A case of macrophage activation syndrome in a child with systemic juvenile idiopathic arthritis
por: Akhenbekova, Aida, et al.
Publicado: (2014)

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis
por: Boom, V., et al.
Publicado: (2015)

Allogeneic Hematopoietic Cell Transplant for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
por: Davidson, Nicole, et al.
Publicado: (2021)

Macrophage Activation Syndrome secondary to Systemic Juvenile Idiopathic Arthritis: A Case Report
por: Kafle, Rishikesh, et al.
Publicado: (2021)

Idiopathic Pulmonary Hemosiderosis in a Child with Recurrent Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

Macrophage activation syndrome during treatment with biological therapy in patients with systemic juvenile idiopathic arthritis
por: Boteanu, Alina Lucica, et al.
Publicado: (2014)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
por: Giancane, Gabriella, et al.
Publicado: (2019)

Posterior reversible encephalopathy syndrome complicating macrophage activation syndrome in a patient with systemic juvenile idiopathic arthritis
por: Tsinti, Maria, et al.
Publicado: (2014)

Significance of Macrophage Subtypes in the Peripheral Blood of Children with Systemic Juvenile Idiopathic Arthritis
por: Feng, Dan, et al.
Publicado: (2021)

Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: a retrospective study on 7 patients
por: Dizdarevic, Aida Omercahic, et al.
Publicado: (2014)

Macrophage activation syndrome due to systemic onset juvenile idiopathic arthritis in a case with liver transplantation
por: Ozturk, Kubra, et al.
Publicado: (2014)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Shimizu, Masaki, et al.
Publicado: (2020)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
por: Kostik, Mikhail M., et al.
Publicado: (2022)

Evaluation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis: A Single Center Experience
por: Høeg, Pia Elkjær, et al.
Publicado: (2022)

Surgical Treatment of Juvenile Idiopathic Arthritis in the Era of Novel Drug Therapies
por: Klein, Céline, et al.
Publicado: (2023)

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
por: Swart, Joost, et al.
Publicado: (2018)

Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis
por: Duurland, Chantal L., et al.
Publicado: (2014)

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
por: Choida, Varvara, et al.
Publicado: (2021)

Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome: Important Differential for Juvenile Idiopathic Arthritis
por: Kakkar, Ritu Manoj, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3r0aluoa58d9pm9th6g6ias6es